- Home
- ZTR vs RIGL Comparison
ZTR vs RIGL Comparison
Compare ZTR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- RIGL
- Stock Information
- Founded
- ZTR 1988
- RIGL 1996
- Country
- ZTR Australia
- RIGL United States
- Employees
- ZTR N/A
- RIGL N/A
- Industry
- ZTR Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- RIGL Health Care
- Exchange
- ZTR Nasdaq
- RIGL Nasdaq
- Market Cap
- ZTR 349.4M
- RIGL 335.5M
- IPO Year
- ZTR N/A
- RIGL 2000
- Fundamental
- Price
- ZTR $6.37
- RIGL $38.85
- Analyst Decision
- ZTR
- RIGL Buy
- Analyst Count
- ZTR 0
- RIGL 5
- Target Price
- ZTR N/A
- RIGL $38.20
- AVG Volume (30 Days)
- ZTR 219.4K
- RIGL 995.6K
- Earning Date
- ZTR 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- ZTR 12.09%
- RIGL N/A
- EPS Growth
- ZTR N/A
- RIGL N/A
- EPS
- ZTR N/A
- RIGL 5.43
- Revenue
- ZTR N/A
- RIGL $267,921,000.00
- Revenue This Year
- ZTR N/A
- RIGL $59.93
- Revenue Next Year
- ZTR N/A
- RIGL N/A
- P/E Ratio
- ZTR N/A
- RIGL $7.15
- Revenue Growth
- ZTR N/A
- RIGL 105.62
- 52 Week Low
- ZTR $4.50
- RIGL $12.66
- 52 Week High
- ZTR $6.60
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ZTR 64.07
- RIGL 68.57
- Support Level
- ZTR $6.27
- RIGL $39.00
- Resistance Level
- ZTR $6.35
- RIGL $42.08
- Average True Range (ATR)
- ZTR 0.04
- RIGL 2.32
- MACD
- ZTR 0.01
- RIGL -0.37
- Stochastic Oscillator
- ZTR 85.06
- RIGL 53.26
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.